Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications
Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications
复制标题
DOI：
10.1093/ajcp/aqx162
复制
发表时间：
2018-03-01
影响因子：
3.5
通讯作者：
Gong, Yun
中科院分区：
文献类型：
--
作者：
He, Jing;Huo, Lei;Gong, Yun
目的：炎性乳腺癌（Inflammatory breast carcinoma，IBC）是一种罕见的乳腺癌，但却是最致命的乳腺癌. IBC中程序性死亡配体1（PD-L1）的表达已经被充分研究。方法：在这项研究中，使用美国食品和药物管理局批准的抗体克隆（28-8）和检测系统，用PD-L1抗体对68个IBC的组织微阵列进行免疫染色，以选择患有非小细胞肺癌和黑色素瘤的患者进行抗PD-L1治疗。结果：在68例样本中，有25例（36.8%）发现PD-L1表达阳性，但与检查的临床病理变量无显著相关性。总生存期（OS）的单变量分析显示，OS较差与PD-L1阳性、雌激素受体阴性和三阴性状态显著相关。PD-L1阳性IBC患者的5年OS率为36.4%，PD-L1阴性IBC患者的5年OS率为47.3%。在多变量分析中，PD-L1状态仍然是统计学上独立的预测OS。结论：这些研究结果表明，PD-L1抑制剂可能会改善PD-L1阳性IBC患者的临床结局。
Objectives: Inflammatory breast carcinoma (IBC) is rare but is the most lethal type of breast cancer. Programmed death ligand 1 (PD-L1) expression in IBCs has been understudied.Methods: In this study, tissue microarrays of 68 IBCs were immunostained with a PD-L1 antibody using an antibody clone (28-8) and detection system approved by the US Food and Drug Administration for selecting patients with non-small cell lung cancer and melanoma for anti-PD-L1 therapy.Results: Positive PD-L1 expression was found in 25 (36.8%) of 68 samples but was not significantly associated with the clinicopathologic variables examined. Univariate analysis of overall survival (OS) revealed that worse OS was significantly associated with positive PD-L1, negative estrogen receptor, and triple-negative status. The 5-year OS rate was 36.4% for patients with PD-L1-positive IBC and 47.3% for those with PD-L1-negative IBC. In multivariate analyses, PD-L1 status remained a statistically independent predictor of OS.Conclusions: These findings indicate that PD-L1 inhibitors could potentially improve the clinical outcome of patients with PD-L1-positive IBC.